Geduld E E adds EXACT Sciences Corporation (EXAS) to its portfolio

EXACT Sciences Corporation (EXAS) : Geduld E E added new position in EXACT Sciences Corporation during the most recent quarter end. The investment management firm now holds 42,500 shares of EXACT Sciences Corporation which is valued at $885,700 , the company said in a statement filed on Aug 8, 2016 with the SEC.EXACT Sciences Corporation makes up approximately 1.22% of Geduld E E’s portfolio.

Other Hedge Funds, Including , Isthmus Partners boosted its stake in EXAS in the latest quarter, The investment management firm added 5,000 additional shares and now holds a total of 16,200 shares of EXACT Sciences Corporation which is valued at $337,608. EXACT Sciences Corporation makes up approx 0.11% of Isthmus Partners’s portfolio.Sheaff Brock Investment Advisors reduced its stake in EXAS by selling 2,500 shares or 19.53% in the most recent quarter. The Hedge Fund company now holds 10,300 shares of EXAS which is valued at $198,275. EXACT Sciences Corporation makes up approx 0.02% of Sheaff Brock Investment Advisors’s portfolio. Cable Hill Partners sold out all of its stake in EXAS during the most recent quarter. The investment firm sold 341 shares of EXAS which is valued $6,564. Quantbot Technologies Lp sold out all of its stake in EXAS during the most recent quarter. The investment firm sold 287 shares of EXAS which is valued $5,249.

EXACT Sciences Corporation opened for trading at $21.93 and hit $22.8 on the upside on Monday, eventually ending the session at $21.49, with a gain of 1.42% or 0.3 points. The heightened volatility saw the trading volume jump to 52,46,626 shares. Company has a market cap of $2,113 M.

On the company’s financial health, EXACT Sciences Corporation reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $-0.55. The company had revenue of $21.20 million for the quarter, compared to analysts expectations of $18.50 million. The company’s revenue was up 161.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.

Many Wall Street Analysts have commented on EXACT Sciences Corporation. Company shares were Reiterated by Craig Hallum on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $18 .Company shares were Reiterated by Jefferies on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 20 from a previous price target of $13 .Company shares were Reiterated by The Benchmark Company on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 14 from a previous price target of $9 .

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *